Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress

Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress

May 28, 2018 New analyses including adults enrolled in the Phase 3 PALISADE trial of AR101 show efficacy across the entire intent-to-treat population of peanut-allergic patients ages 4-55 New immunologic subset analyses show that AR101 treatment was linked to depletion

Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

— Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy — BRISBANE, Calif.–(BUSINESS WIRE)–May 15, 2018– Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially

Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June

BRISBANE, Calif.–(BUSINESS WIRE)–May 9, 2018– Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in May and June: Event: Bank of